Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%

Endocrine Practice

Volumn 19, Issue 1, 2013, Pages 64-72

  King, Allen B ^a   Montanya, Eduard ^b   Pratley, Richard E ^c   Blonde, Lawrence ^d   Svendsen, Claus Bo ^e   Donsmark, Morten ^e   Sesti, Giorgio ^f  

^a Diabetes Care Center   (United States)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c FLORIDA HOSPITAL   (United States)

^d OCHSNER MEDICAL CENTER   (United States)

^e NOVO NORDISK A S   (Denmark)

^f UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE; VENOM;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HYPOGLYCEMIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; PYRAZINES; TREATMENT OUTCOME; TRIAZOLES; VENOMS;

EID: 84881486681     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12232.OR     Document Type: Article

References (39)

1. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control 2009. Endocr Pract. 2009;15:540-559.
2. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154:602-613.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.
4. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-1253.
5. Kahn SE, Lachin JM, Zinman B, et al. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes. 2011;60:1552-1560.
6. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17(Suppl 2):1-53.
7. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care. 2012;35(Suppl 1):S11-S63.
8. Petrie JR, Adler A, Vella S. What to add in with metformin in type 2 diabetes? QJM. 2011;104:185-192.
9. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care. 2006;29:2137-2139. (Pubitemid 44871202)
10. Belsey J, Krishnarajah G. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. Diabetes Obes Metab. 2008;10(Suppl 1):1-7.
11. Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:959-969.
12. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24:2943-2952.
13. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649-1655.
14. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Care. 2009;32:84-90.
15. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447-1456.
16. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65-74.
17. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
18. Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33:1300-1303.
19. Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65:397-407.
20. DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27:309-317.
21. Henry RR, Buse JB, Sesti G, et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A1C: a meta-analysis of the liraglutide development program. Endocr Pract. 2011;17:906-913.
22. Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab. 2012;14:228-233.
23. Bradley C. Diabetes Treatment Satisfaction Questionnaire. In: Bradley C, ed. Handbook of Psychology and Diabetes. Chur, Switzerland: Harwood Academic Publishers; 1994:111-132.
24. Garber A, Matthews D, Holst J, et al. The effect of diabetes duration on the response to liraglutide and glimepiride in type 2 diabetes. Diabetes. 2010;59(Suppl 1):A197.
25. Ratner R, Brett J, Khutoryansky N, Aroda V. Identifying predictors of response to liraglutide in type 2 diabetes using recursive partitioning analysis. Diabetes. 2012;61(Suppl 1):A267.
26. Gallwitz B, Guzman J, Dotta F, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet. 2012;379:2270-2278.
27. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9:194-205. (Pubitemid 46206563)
28. Esposito K, Chiodini P, Ceriello A, Giugliano D. A nomogram to estimate the proportion of patients at hemoglobin A1C target <7% with noninsulin antidiabetic drugs in type 2 diabetes: systematic review of 137 randomized controlled trials with 39 845 patients. Acta Diabetol. 2012;DOI: 10.1007/s00592-012-0370-9 [Epub ahead of print].
29. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632-2637. (Pubitemid 44912190)
30. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type2 diabetes. Diabetes. 2004;53:1187-1194. (Pubitemid 38569002)
31. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78:675-688. (Pubitemid 41773643)
32. Merck Sharp & Dohme Corp. Januvia PI. Available at: http://www.merck.com/product/usa/pi-circulars/j/januvia/januvia-pi.pdf. Accessed July 16, 2012.
33. Novo Nordisk. Victoza PI. Available at: http://www.novo-pi.com/victoza. pdf. Accessed May 16, 2012.
34. Amylin Pharmaceuticals, Inc. Byetta PI. Available at: http://documents.byetta.com/Byetta-PI.pdf. Accessed May 16, 2012.
35. Peyrot M, Rubin RR. How does treatment satisfaction work? Diabetes Care. 2009;32:1411-1417.
36. Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse JB. Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. Diabet Med. 2011;28:715-723.
37. Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med. 2011;28:333-337.
38. Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;DOI: 10.2337/dc11-2113 [Epub ahead of print].
39. Gough S, Madsbad S, Jensen K, Falahati A, Bain S. Liraglutide is associated with reduced rates of hypoglycemic events versus glimepiride when achieving target HbA1c. Diabetes 2010;59(Suppl 1):A208-A209.